Processa Pharmaceuticals, Inc. (PCSA): R&D Expense
$7.81M
Year ended 2025-12-31
$6.23M
Trailing 12 months to 2026-06-30
-12.1%
3-year compound annual growth
+19.7%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.81M | +7.4% | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $7.27M | +25.3% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $5.80M | -49.5% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $11.49M | +67.1% | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $6.88M | +116.8% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $3.17M | +36.7% | 2022-03-30, From 2020-01-01 |
| 2019-12-31 | $2.32M | -24.8% | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | $3.09M | +220.0% | 2020-03-06, From 2018-01-01 |
| 2017-12-31 | $964.2K | n/c | 2019-04-08, From 2017-01-01 |
| 2016-12-31 | $1.54M | n/m | 2018-04-16, From 2016-01-01 |
| 2015-12-31 | $29.2K | -83.6% | 2017-09-25, From 2015-01-01 |
| 2014-12-31 | $178.1K | n/c | 2017-06-19, From 2014-01-01 |
| 2013-12-31 | $267.1K | -40.4% | 2015-04-14, From 2013-01-01 |
| 2012-12-31 | $448.0K | n/a | 2014-03-27, From 2012-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | 2025-12-31 | $7.81M | +7.4% |
| Dermata Therapeutics, Inc. (DRMA) | 2025-12-31 | $2.93M | -64.3% |
| Acurx Pharmaceuticals, Inc. (ACXP) | 2025-12-31 | $1.83M | -66.1% |
| Silo Pharma, Inc. (SILO) | 2025-12-31 | $2.16M | -8.8% |
| Rocket One Inc. (RKTO) | 2025-12-31 | $5.95M | +83.0% |
| Oncolytics Biotech Inc (ONCY) | 2025-12-31 | $13.31M | -13.8% |
| GT Biopharma, Inc. (GTBP) | 2025-12-31 | $3.47M | -40.1% |
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $10.38M | +43.7% |
| Lunai Bioworks Inc. (LNAI) | 2025-06-30 | $537.4K | -80.2% |
Compare PCSA, DRMA, ACXP, SILO side by side · Screen every company in Pharmaceutical Preparations ↗